Shares in Novo Nordisk fell as much as six per cent on Friday to their lowest since August 2021, extending recent losses to ...

Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions ...

Novo Nordisk shares dropped as low as $46.90 in Thursday’s session, their lowest level since January 2022, following a profit warning.

However, Novo Nordisk has warned that the rise in copycat versions of its weight-loss drug in the U.S. and competition from Lilly across several markets is expected to hurt Wegovy sales this year.

Obesity drugmakers Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO) traded higher in the premarket on Friday after The Washington ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...